Skip to main content

Matthew B Schabath, PhD

Research Reports
10/18/2019
Abstract: Biomarker-driven therapies are the gold standard of treatment in lung cancer. Recent studies suggest a higher prevalence of specific targetable biomarkers among Hispanic/Latinos (H/L) than non-Hispanic...
Abstract: Biomarker-driven therapies are the gold standard of treatment in lung cancer. Recent studies suggest a higher prevalence of specific targetable biomarkers among Hispanic/Latinos (H/L) than non-Hispanic...
...
10/18/2019
Journal of Clinical Pathways